Combination Chemotherapy Consisting of Gemcitabine And Topotecan in Treating Patients With Refractory or Recurrent Ovarian or Fallopian Tube Cancer

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically documented refractory or recurrent ovarian epithelial or fallopian tube cancer
• •No borderline ovarian cancer
• •Extra-ovarian papillary serous tumors eligible
• •Must not be eligible for any higher priority phase II or III GOG protocol
• •PATIENT CHARACTERISTICS:
• •Age:
• •18 and over
• •Performance status:
• •GOG 0-2
• •Life expectancy:
• •Not specified
• •Hematopoietic:
• •Granulocyte count at least 1,500/mm\^3
• •Platelet count at least 100,000/mm\^3
• •Hepatic:
• •SGOT no greater than 3 times upper limit of normal (ULN)
• •Bilirubin no greater than 1.5 mg/dL
• •Elevated levels of alkaline phosphatase allowed
• •Renal:
• •Creatinine no greater than 1.5 mg/dL
• •Cardiovascular:
• •No angina pectoris or clinically significant multifocal uncontrolled cardiac dysrhythmias
• •No uncontrolled hypertension
• •Other:
• •No other active malignancy
• •No prior malignancy within the past 5 years except nonmelanomatous skin cancer
• •No active infection
• •No underlying medical problem that would prevent compliance
• •No known hypersensitivity to E. coli-derived drug preparations
• •Fertile patients must use effective contraception
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy:
• •Not specified
• •Chemotherapy:
• •Must have received at least 1 prior platinum- and paclitaxel-based regimen
• •At least 4 weeks since prior chemotherapy
• •No prior topotecan and/or gemcitabine
• •No prior chemotherapy for a different prior malignancy
• •Endocrine therapy:
• •Not specified
• •Radiotherapy:
• •No prior radiotherapy to more than 10% of bone marrow
• •At least 2 weeks since limited field radiation therapy
• •Surgery:
• •Not specified